Cover Image
市場調查報告書

Galapagos NV- 產品平台檢討

Galapagos NV - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 204915
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
Galapagos NV- 產品平台檢討 Galapagos NV - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 64 Pages
簡介

生物科技企業Galapagos NV (Galapagos)致力於癌症的轉移和嚴重的併發症治療藥物integrin受體拮抗劑的研究開發。同時其產器也有用於治療免疫疾病和發炎。

本報告提供Galapagos NV 的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Galapagos NV的基本資料

Galapagos NV概要

  • 主要資訊
  • 企業資料

Galapagos NV:R&D概要

  • 主要的治療範圍

Galapagos NV:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Galapagos NV:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Galapagos NV:藥物簡介

  • GLPG-0634
  • GLPG-0974
  • GLPG-0492
  • GLPG-1205
  • GLPG-1179
  • GLPG-1492
  • GLPG-1577
  • GLPG-1690
  • GLPG-1790
  • GLPG-1837
  • Monoclonal Antibodies for Bone and Joint disease
  • Drugs for Cancer
  • Drugs for Cystic Fibrosis and COPD
  • Drugs for Osteoporosis
  • Small Molecules for Cancer
  • Small Molecules for Metabolic, Cardiovascular and Inflammatory Disease

Galapagos NV:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Galapagos NV:最近的開發平台趨勢

Galapagos NV:暫停中的計劃

Galapagos NV:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • GLPG-0187
    • GLPG-0259
    • GLPG-0492
    • GLPG-1332
    • Small Molecules for Osteoarthritis

Galapagos NV:總公司和子公司的所地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08084CDB

Summary

Global Markets Direct's, 'Galapagos NV - Product Pipeline Review - 2016', provides an overview of the Galapagos NV's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Galapagos NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Galapagos NV
  • The report provides overview of Galapagos NV including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Galapagos NV's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Galapagos NV's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Galapagos NV's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Galapagos NV
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Galapagos NV's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Galapagos NV Snapshot
    • Galapagos NV Overview
    • Key Information
    • Key Facts
  • Galapagos NV - Research and Development Overview
    • Key Therapeutic Areas
  • Galapagos NV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Galapagos NV - Pipeline Products Glance
    • Galapagos NV - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Galapagos NV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Galapagos NV - Drug Profiles
    • filgotinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1205
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1690
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1837
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DT-200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1972
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2222
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2451
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOR-106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1492
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1790
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-1837 + GLPG-2222 + GLPG-2665
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2534
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2665
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2737
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2851
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLPG-2938
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Galapagos NV - Pipeline Analysis
    • Galapagos NV - Pipeline Products by Target
    • Galapagos NV - Pipeline Products by Route of Administration
    • Galapagos NV - Pipeline Products by Molecule Type
    • Galapagos NV - Pipeline Products by Mechanism of Action
  • Galapagos NV - Recent Pipeline Updates
  • Galapagos NV - Dormant Projects
  • Galapagos NV - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GLPG-0187
      • GLPG-0259
      • GLPG-1179
      • GLPG-1205
      • GLPG-1332
      • GLPG-1577
  • Galapagos NV - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Galapagos NV, Key Information
  • Galapagos NV, Key Facts
  • Galapagos NV - Pipeline by Indication, 2016
  • Galapagos NV - Pipeline by Stage of Development, 2016
  • Galapagos NV - Monotherapy Products in Pipeline, 2016
  • Galapagos NV - Combination Treatment Modalities in Pipeline, 2016
  • Galapagos NV - Partnered Products in Pipeline, 2016
  • Galapagos NV - Partnered Products/ Combination Treatment Modalities, 2016
  • Galapagos NV - Out-Licensed Products in Pipeline, 2016
  • Galapagos NV - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Galapagos NV - Phase II, 2016
  • Galapagos NV - Phase I, 2016
  • Galapagos NV - Preclinical, 2016
  • Galapagos NV - Discovery, 2016
  • Galapagos NV - Pipeline by Target, 2016
  • Galapagos NV - Pipeline by Route of Administration, 2016
  • Galapagos NV - Pipeline by Molecule Type, 2016
  • Galapagos NV - Pipeline Products by Mechanism of Action, 2016
  • Galapagos NV - Recent Pipeline Updates, 2016
  • Galapagos NV - Dormant Developmental Projects,2016
  • Galapagos NV - Discontinued Pipeline Products, 2016
  • Galapagos NV, Subsidiaries

List of Figures

  • Galapagos NV - Pipeline by Top 10 Indication, 2016
  • Galapagos NV - Pipeline by Stage of Development, 2016
  • Galapagos NV - Monotherapy Products in Pipeline, 2016
  • Galapagos NV - Pipeline by Target, 2016
  • Galapagos NV - Pipeline by Route of Administration, 2016
  • Galapagos NV - Pipeline by Molecule Type, 2016
  • Galapagos NV - Pipeline Products by Mechanism of Action, 2016
Back to Top